A Study of LY3502970 in Healthy Participants

• Status: Completed
• Trial end date: 2020-11-02
• Target enrollment: 0
• Participant gender: All

Summary

The main purposes of this study are to determine:

• The safety of LY3502970 and any side effects that might be associated with it.

• How much LY3502970 gets into the bloodstream and how long it takes the body to get rid of it.

This study has 5 parts (A, B, C, D, and E). Parts A and D involve a single dose of LY3502970 and will last about 15 days. Part B and E involve multiple doses of LY3502970 and will last about 4 weeks. Part C involves two single doses of LY3502970 and will last about 29 days. Each participant will enroll in only one part. Screening must be completed within 28 days before study start. This study is for research purposes only, and is not intended to treat any medical condition.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Eli Lilly and Company
• Treatments: Atorvastatin; Midazolam; Simvastatin

Criteria

Inclusion Criteria:

• Healthy male or females, as determined by medical history

• Have safety laboratory results within normal reference ranges

Exclusion Criteria:

• Have known allergies to LY3502970, glucagon-like peptide-1 (GLP-1) analogs, related compounds

• Abnormal electrocardiogram (ECG) at screening

• Significant history of or current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological or neurological disorders.